Our essential knowhow is an extensive expertise in the research of human regulatory T cells, their purification from blood products in the clean room and the development of a patented process for the activation of human regulatory T cells.
Through the special manufacturing process of ATreg, we obtain a clinically highly efficient cellular product from leukaphereses that can be made available to patients within 24 hours.
Comprehensive protection rights protect ATreg. This includes the special activation process of Treg, the use of these cells as an ATMP, but also the test systems for the identification of new Treg activating proteins. Some patents have already been granted in the US, Canada, Japan and Europe.
In addition, we received Orphan Drug Designation for treatment in HSCT by EMA and FDA, providing market exclusivity of 7 years in the US and 10 years in the EU upon first market approval.
>> Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4.
>> In-vitro methods for the detection of treg resistance and autoimmune diseases.